Biogen Inc

NASDAQ:BIIB  
199.75
+6.66 (+3.45%)
Products

Biogen And Ionis Announce Topline Phase 1 Study Results Of Investigational Drug In C9orf72 Amyotrophic Lateral Sclerosis

Published: 03/28/2022 13:01 GMT
Biogen Inc (BIIB) - Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis.
Biogen - Biib078, Investigational Antisense Oligonucleotide for C9orf72-associated Als, Did Not Show Clinical Benefit.
Biogen - Clinical Program Will Be Discontinued.
Biogen Inc - Biib078 Did Not Meet Any Secondary Efficacy Endpoints and It Did Not Demonstrate Clinical Benefit.
Biogen Inc - Participants in Biib078 90 Mg Dose Cohort Trended Toward a Greater Decline Than Those in Placebo Group Across Secondary Endpoints.
Biogen Inc - in Dose Cohorts Up to 60 Mg There Were No Consistent Differences Between Biib078 Group and Placebo Group.